名稱 | ADCC Bioassay Effector Cell F variant (Low Affinit |
型號(hào) | CBP74002 |
報(bào)價(jià) | |
特點(diǎn) | ADCC Bioassay Effector Cell F variant (Low Affinity)- Fcγ-NFAT/Jurkat,母細(xì)胞:Jurkat,培養(yǎng)基:1640+10%FBS |
產(chǎn)品搜索
相關(guān)文章
聯(lián)系我們
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > 腫瘤免疫細(xì)胞株 > CBP74002ADCC Bioassay Effector Cell F variant (Low Affinit
- 詳細(xì)內(nèi)容
I. Background | |
抗體依賴的細(xì)胞介導(dǎo)的細(xì)胞毒性作用(ADCC,antibody-dependent cell-mediated cytotoxicity )是指抗體的 Fab 段結(jié)合病毒感染的細(xì)胞或腫瘤細(xì)胞的抗原表位,其 Fc 段與殺 傷細(xì)胞(NK 細(xì)胞、巨噬細(xì)胞等)表面的 FcR 結(jié)合,介導(dǎo)殺傷細(xì)胞直接殺傷靶細(xì)胞,它是 抗腫瘤的治療性抗體藥物發(fā)生作用的一種作用重要機(jī)制。 | |
II. Description | |
ADCC Bioassay Effector Cell F variant (Low Affinity)-Fcγ-NFAT Jurkat 報(bào)告基因藥靶模型 很好的模擬了體內(nèi) ADCC 的信號(hào)轉(zhuǎn)導(dǎo)過程,原理見下圖所示。
| |
III. Introduction | |
Host Cell: | Jurkat |
Expressed gene: | NFAT-Luc-CD16(F158) |
Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Synonym(s): | Antibody-dependent cell-mediated cytotoxicity |
Freeze Medium: | 90% FBS+10% DMSO |
Culture Medium: | RPMI-1640+10%FBS |
Mycoplasma Testing: | Negative |
Storage: | Immediately upon receipt, store in liquid nitrogen. |
Application(s): | Functional(Report Gene) Assay |
IV. Description of Host Cell Line | |
Organism: | Homo sapiens, human |
Tissue: | Peripheral blood |
Disease: | Acute T cell leukemia |
Morphology: | Lymphoblast |
Growth Properties: | Suspension |
Ⅴ. Representative Data |
Figure 2. Recombinant ADCC Bioassay Effector Cell F variant (Low Affinity)- Fcγ-NFAT/Jurkat expressing CD16.
Figure 3. Dose response of CD20 Ab in ADCC Bioassay Effector Cell F variant (Low Affinity)-Fcγ-NFAT Jurkat (C11) with Raji.